Purchase / New York / United States
Nutrition 21 is pioneering an effort to use patented technology, pharmaceutical research and strategic marketing and distribution partnerships to build its position in therapeutic markets. The company is targeting the diabetes marketplace and related health markets where poor insulin function is a metabolic risk factor. These include obesity, metabolic syndrome, cardiovascular disease and depression. Healthcare providers are most likely to rely on FDA approved drugs as the first course of therapy for patients, particularly those suffering with high-risk chronic diseases. Therefore, Nutrition 21 relies on large-scale double-blind placebo-controlled clinical trials as a key element of its marketing strategy. The company s objective is to translate its scientific findings into trusted brands recognized for their measurable contribution to improving public health and reducing cost of care.
